Literature DB >> 24048067

Influence of tumour micro-environment heterogeneity on therapeutic response.

Melissa R Junttila1, Frederic J de Sauvage.   

Abstract

Tumour formation involves the co-evolution of neoplastic cells together with extracellular matrix, tumour vasculature and immune cells. Successful outgrowth of tumours and eventual metastasis is not determined solely by genetic alterations in tumour cells, but also by the fitness advantage such mutations confer in a given environment. As fitness is context dependent, evaluating tumours as complete organs, and not simply as masses of transformed epithelial cells, becomes paramount. The dynamic tumour topography varies drastically even throughout the same lesion. Heterologous cell types within tumours can actively influence therapeutic response and shape resistance.

Entities:  

Mesh:

Year:  2013        PMID: 24048067     DOI: 10.1038/nature12626

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  119 in total

1.  Distinct epigenetic changes in the stromal cells of breast cancers.

Authors:  Min Hu; Jun Yao; Li Cai; Kurt E Bachman; Frédéric van den Brûle; Victor Velculescu; Kornelia Polyak
Journal:  Nat Genet       Date:  2005-07-10       Impact factor: 38.330

2.  A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy.

Authors:  Qin Mao; Yu Zhang; Xiaoyue Fu; Jianxin Xue; Wenhao Guo; Maobing Meng; Zongguang Zhou; Xianming Mo; You Lu
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-30       Impact factor: 4.553

3.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Authors:  D I Gabrilovich; T Ishida; S Nadaf; J E Ohm; D P Carbone
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

Authors:  Stanley B Kaye; Louis Fehrenbacher; Robert Holloway; Amnon Amit; Beth Karlan; Brian Slomovitz; Paul Sabbatini; Ling Fu; Robert L Yauch; Ilsung Chang; Josina C Reddy
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

6.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Authors:  Vernon T Phan; Xiumin Wu; Jason H Cheng; Rebecca X Sheng; Alicia S Chung; Guanglei Zhuang; Christopher Tran; Qinghua Song; Marcin Kowanetz; Amy Sambrone; Martha Tan; Y Gloria Meng; Erica L Jackson; Franklin V Peale; Melissa R Junttila; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

7.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962

8.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

Review 9.  Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells.

Authors:  Urszula M Polanska; Akira Orimo
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

10.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  839 in total

1.  Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Authors:  Vincent Crenn; Kevin Biteau; Jérôme Amiaud; Clotilde Dumars; Romain Guiho; Luciano Vidal; Louis-Romée Le Nail; Dominique Heymann; Anne Moreau; François Gouin; Françoise Redini
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 2.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 3.  Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics.

Authors:  Mark A Labarge; Bahram Parvin; James B Lorens
Journal:  Adv Drug Deliv Rev       Date:  2014-02-26       Impact factor: 15.470

4.  Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness.

Authors:  Shuya Yano; Yong Zhang; Shinji Miwa; Yasunori Tome; Yukihiko Hiroshima; Fuminari Uehara; Mako Yamamoto; Atsushi Suetsugu; Hiroyuki Kishimoto; Hiroshi Tazawa; Ming Zhao; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2014-05-08       Impact factor: 4.534

5.  Biomechanical forces in tissue engineered tumor models.

Authors:  Letitia K Chim; Antonios G Mikos
Journal:  Curr Opin Biomed Eng       Date:  2018-03-26

Review 6.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

7.  A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.

Authors:  R R Naik; A K Singh; A M Mali; M F Khirade; S A Bapat
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 8.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

Review 9.  Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Authors:  Deepika Neelakantan; David J Drasin; Heide L Ford
Journal:  Cell Adh Migr       Date:  2014-10-16       Impact factor: 3.405

Review 10.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.